UnitedHealth (NYSE:UNH) closed in the green after seven consecutive sessions of losses, as the company’s shares closed 0.86% higher at $327.58 on Wednesday.
In the preceding seven sessions, the company lost over 4.9%, compared to a rise of 1.2% in the S&P 500 Index. Similarly, shares of the company have gone down by over 35.2% compared to a gain of 17.5% in the broader S&P 500 Index in 2025.
According to Seeking Alpha analyst Envision Research, UNH has worked through recent headwinds, with profits recovering and a foundation in place for renewed growth. With a forward P/E of 20.5x and potential for double-digit return on investment, Envision Research believes UNH offers an attractive risk/reward profile.
Analyst Pierre Axel Gide suggests the company is well-positioned despite two difficult years of cyber incidents, leadership turnover, and regulatory investigations. The company’s scale and diversified healthcare operations form a durable competitive moat that supports the long-term investment.
However, according to KM Capital, UNH faces elevated uncertainty due to potential changes in ACA subsidies and major company repositioning plans for 2026. Due to persistent uncertainties and fair valuation, it downgraded UNH to Hold.
Looking at Seeking Alpha’s Quant rating, UNH has a Hold rating with a score of 3.21 out of 5. The company was rated A+ for profitability, while it got an F for growth and a B- for valuation.
However, Wall Street analysts appeared bullish, as 19 rated the stock a Buy or above, 6 rated it a Hold, and 2 considered it a Sell or lower.
Similarly, Seeking Alpha analysts also issued a Buy call for UNH with a score of 3.84 out of 5.